Welcome to “The Whispered Roar,” a column where I will describe what it’s like living with a neuromuscular autoimmune disease called myasthenia gravis (MG). I was officially diagnosed with generalized MG in 2018, although I had been battling symptoms since 2011. My journey to diagnosis is not an uncommon…
Immunovant is moving forward with its Phase 3 clinical trial in the U.S. to evaluate the investigational myasthenia gravis (MG) therapy batoclimab in the first half of this year. The announcement came after the company reached an agreement with the division of neurology within the U.S. Food…
Like many others in the past two years, I’ve become a first-time houseplant owner. After “extensive” research, which involved perhaps a couple Google searches, I bought a Calathea ornata, or pinstripe Calathea, a beautiful plant with thin, pink-striped leaves. I wish I could say I chose it for…
Throughout 2021, Myasthenia Gravis News has brought you coverage on the latest scientific advancements and clinical trials related to myasthenia gravis (MG). We look forward to continuing to be a resource to the MG community across 2022. Here are the top 10 most-read MG news stories of 2021, along with a…
Infants born to women with myasthenia gravis (MG) may develop a rare condition called transient neonatal myasthenia gravis (TNMG), which needs to be properly recognized in order to be appropriately managed, a new report highlights. “A neonate [newborn] born to a mother with MG is at risk for…
Merck KGaA has acquired Chord Therapeutics and the rights to continue developing CRD1 (cladribine), Chord’s lead candidate for treatment of generalized myasthenia gravis. “I am particularly pleased that Chord’s focus on severe, rare neurological conditions will be complemented by Merck’s established leadership with cladribine,” Arthur Roach, founder and…
The U.S. Food and Drug Administration (FDA) has accepted and placed on priority review an application seeking the approval of Ultomiris (ravulizumab-cwvz) to treat adults with generalized myasthenia gravis (gMG). The FDA set April through June as a target date range for its decision. Ultomiris is a monoclonal antibody…
New Year’s seems to hold a different meaning for everyone. Some see it as an opportunity to chug champagne, while others dedicate their time to brainstorming resolutions. I’ve never been very excited about the holiday. I’m not a big drinker, and have failed at too many resolutions to…
Treatment with Ultomiris (ravulizumab-cwvz), a complement-blocking therapy, quickly eased symptom severity in adults with generalized myasthenia gravis (gMG), according to data from a Phase 3 trial. Findings were shared at the Myasthenia Gravis Foundation of America (MGFA) Scientific Sessions 2021 in the presentation, “Efficacy and safety…
Vyvgart (efgartigimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, the therapy’s developer, Argenx, announced. According to Argenx, this patient group represents about 85% of all with generalized MG. “Today is…
Get regular updates to your inbox.
